Literature DB >> 22184402

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.

M Pia Morelli1, Emiliano Calvo, Esther Ordoñez, Michael J Wick, Belen-Rubio Viqueira, Pedro P Lopez-Casas, Elizabeth Bruckheimer, Antonio Calles-Blanco, David Sidransky, Manuel Hidalgo.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22184402      PMCID： PMC4874230          DOI： 10.1200/JCO.2011.36.9678

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.

Authors:  M Raphael Pfeffer; Yoav Talmi; Raphael Catane; Zvi Symon; Ady Yosepovitch; Mark Levitt
Journal:  Oral Oncol       Date:  2006-06-06       Impact factor: 5.337

2.  An in vivo platform for translational drug development in pancreatic cancer.

Authors:  Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

Review 3.  Management of malignant tumors of the salivary glands.

Authors:  R H Spiro
Journal:  Oncology (Williston Park)       Date:  1998-05       Impact factor: 2.990

4.  Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.

Authors:  Sébastien J Hotte; Eric W Winquist; Elizabeth Lamont; Mary MacKenzie; Everett Vokes; Eric X Chen; Shirley Brown; Gregory R Pond; Anthony Murgo; Lillian L Siu
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

5.  Distant metastasis in adenoid cystic carcinoma of salivary origin.

Authors:  R H Spiro
Journal:  Am J Surg       Date:  1997-11       Impact factor: 2.565

6.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

7.  Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Authors:  Maria C Villarroel; N V Rajeshkumar; Ignacio Garrido-Laguna; Ana De Jesus-Acosta; Siân Jones; Anirban Maitra; Ralph H Hruban; James R Eshleman; Alison Klein; Daniel Laheru; Ross Donehower; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-12-06       Impact factor: 6.261

Review 8.  Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

Authors:  Scott A Laurie; Alan L Ho; Matthew G Fury; Eric Sherman; David G Pfister
Journal:  Lancet Oncol       Date:  2010-12-10       Impact factor: 41.316

9.  Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

Authors:  Mark Agulnik; Ezra W E Cohen; Roger B Cohen; Eric X Chen; Everett E Vokes; Sebastien J Hotte; Eric Winquist; Scott Laurie; D Neil Hayes; Janet E Dancey; Shirley Brown; Gregory R Pond; Ian Lorimer; Manijeh Daneshmand; James Ho; Ming-Sound Tsao; Lillian L Siu
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

10.  Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Authors:  Daniel D Von Hoff; Patricia M LoRusso; Charles M Rudin; Josina C Reddy; Robert L Yauch; Raoul Tibes; Glen J Weiss; Mitesh J Borad; Christine L Hann; Julie R Brahmer; Howard M Mackey; Bertram L Lum; Walter C Darbonne; James C Marsters; Frederic J de Sauvage; Jennifer A Low
Journal:  N Engl J Med       Date:  2009-09-02       Impact factor: 91.245
View more
  49 in total

Review 1.  Colorectal cancer models for novel drug discovery.

Authors:  Daniel Golovko; Dmitriy Kedrin; Ömer H Yilmaz; Jatin Roper
Journal:  Expert Opin Drug Discov       Date:  2015-08-21       Impact factor: 6.098

Review 2.  Examining the utility of patient-derived xenograft mouse models.

Authors:  Samuel Aparicio; Manuel Hidalgo; Andrew L Kung
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

3.  Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.

Authors:  Elena Garralda; Keren Paz; Pedro P López-Casas; Siân Jones; Amanda Katz; Lisa M Kann; Fernando López-Rios; Francesca Sarno; Fátima Al-Shahrour; David Vasquez; Elizabeth Bruckheimer; Samuel V Angiuoli; Antonio Calles; Luis A Diaz; Victor E Velculescu; Alfonso Valencia; David Sidransky; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

4.  Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization.

Authors:  Shuyang Sun; Zhiyuan Zhang
Journal:  Front Med       Date:  2016-02-29       Impact factor: 4.592

5.  B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.

Authors:  Leo Zhang; Krystle Nomie; Hui Zhang; Taylor Bell; Lan Pham; Sabah Kadri; Jeremy Segal; Shaoying Li; Shouhao Zhou; David Santos; Shawana Richard; Shruti Sharma; Wendy Chen; Onyekachukwu Oriabure; Yang Liu; Shengjian Huang; Hui Guo; Zhihong Chen; Wenjing Tao; Carrie Li; Jack Wang; Bingliang Fang; Jacqueline Wang; Lei Li; Maria Badillo; Makhdum Ahmed; Selvi Thirumurthi; Steven Y Huang; Yiping Shao; Laura Lam; Qing Yi; Y Lynn Wang; Michael Wang
Journal:  Clin Cancer Res       Date:  2017-03-27       Impact factor: 12.531

6.  Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.

Authors:  Yungchang Chen; Ran Zhang; Li Wang; Arlene M Correa; Apar Pataer; Yi Xu; Xiaoshan Zhang; Chenghui Ren; Shuhong Wu; Qing H Meng; Junya Fujimoto; Vanessa B Jensen; Mara B Antonoff; Wayne L Hofstetter; Reza J Mehran; George Pisimisis; David C Rice; Boris Sepesi; Ara A Vaporciyan; Garrett L Walsh; Stephen G Swisher; Jack A Roth; John V Heymach; Bingliang Fang
Journal:  Cancer       Date:  2019-07-09       Impact factor: 6.860

Review 7.  Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Authors:  Annette T Byrne; Denis G Alférez; Frédéric Amant; Daniela Annibali; Joaquín Arribas; Andrew V Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K Chang; Robert B Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S Gail Eckhardt; Eva Gonzalez-Suarez; Els Hermans; Manuel Hidalgo; Monika A Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild Mari Mælandsmo; Elisabetta Marangoni; Jean-Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G Palmer; Daniel S Peeper; Pier Giuseppe Pelicci; Alejandro Piris-Gimenez; Sergio Roman-Roman; Oscar M Rueda; Joan Seoane; Violeta Serra; Laura Soucek; Dominique Vanhecke; Alberto Villanueva; Emilie Vinolo; Andrea Bertotti; Livio Trusolino
Journal:  Nat Rev Cancer       Date:  2017-01-20       Impact factor: 60.716

8.  Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.

Authors:  Chuncheng Hao; Li Wang; Shaohua Peng; Mengru Cao; Hongyu Li; Jing Hu; Xiao Huang; Wei Liu; Hui Zhang; Shuhong Wu; Apar Pataer; John V Heymach; Agda Karina Eterovic; Qingxiu Zhang; Kenna R Shaw; Ken Chen; Andrew Futreal; Michael Wang; Wayne Hofstetter; Reza Mehran; David Rice; Jack A Roth; Boris Sepesi; Stephen G Swisher; Ara Vaporciyan; Garrett L Walsh; Faye M Johnson; Bingliang Fang
Journal:  Cancer Lett       Date:  2014-11-18       Impact factor: 8.679

9.  Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Authors:  M Teresa Agulló-Ortuño; C Vanesa Díaz-García; Alba Agudo-López; Carlos Pérez; Ana Cortijo; Luis Paz-Ares; Fernando López-Ríos; Francisco Pozo; Javier de Castro; Hernán Cortés-Funes; José A López Martín
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-01       Impact factor: 4.553

10.  S100A4 in esophageal cancer: is this the one to blame?

Authors:  Jianyuan Chai; M Mazen Jamal
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.